Skip to content
‹ Back to IndustriesSciences

What is the Key to Sustainability in the Final Frontier?

On the Space to Grow podcast, Astroscale's Chris Blackerby and Charity Weeden discuss the technology, international policy, and scalability required for sustainable space exploration. They draw on experience spanning civil, commercial, and defense sectors to address the next generation of space sustainability challenges, including orbital debris and responsible use of space.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · AstroscaleCharity WeedenChris BlackerbyInternational
Share

Key takeaways

01

Sustainability in space requires coordination across civil, commercial, and defense sectors.

02

International policy frameworks are critical to governing debris removal and orbital resource management.

03

Scalable technology solutions are essential for the long-term viability of space operations.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On the Space to Grow podcast, Astroscale’s Chris Blackerby and Charity Weeden bring their compelling experience and expertise to map out the technology, international policy, and scalability that will define the next generation of space exploration.

There are three distinct areas of space exploration—civil, commercial, and defense. It’s rare to find a leader that has contributed to all three. Space to Grow welcomed such a pioneer, Pamela Melroy. Melroy spoke with hosts Chris Blackerby and Charity Weeden about her career and the importance of all three aspects cooperating.

Melroy has an impressive career. She was an astronaut, flying three times, and was commander of one of those missions. She held other positions at NASA, the FAA, DARPA, and Lockheed Martin. Now she’s the Director of Space Technology and Policy for Nova Systems, an engineering and technology solutions partner.

Melroy described her career path. “I wanted to be an astronaut and didn’t outgrow it. I had a singular focus on it.

“Sustainability is a national problem, and cooperation essential. The International Space Station represents this. It requires trust to go forward.” – Pam Melroy

Then it was time to stop flying, and I wanted to keep working on important things and another mountain to climb.” It became mountains as she traversed through all aspects of the space world, learning and adapting along the way.

Her experience taught her that the three areas of space were in deep silos. Each has different agendas, motivations, and priorities. Those don’t always align, even for many fundamental areas. She noted the example of servicing satellites. “NASA knows all about it, and I did it in space. However, there’s a fundamentally different approach to the problem.”

Additionally, there is the complex problem of space debris removal, requiring international collaboration, but it’s not happening. Melroy said, “It’s easy to point the finger at the policy issue as holding us back. Sustainability is a national problem, and cooperation essential. The International Space Station represents this. It requires trust to go forward.”

Listen to Previous Episodes Here!

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte's December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own financial outlook but only 41% optimistic about the global economy, the mood the program is built for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

CB
Chris Blackerby

Group COO at Astroscale

Chris Blackerby is Group COO at Astroscale, a leading company focused on satellite servicing and orbital sustainability. He previously served as NASA's Attache to Asia, giving him rare experience across civil, commercial, and defense space sectors. He is a recognized voice on space debris removal, international space policy, and the future of sustainable space exploration.

CW
Charity Weeden

Vice President, Global Space Policy

Astroscale

Charity Weeden serves as Vice President of Global Space Policy at Astroscale, where she focuses on advancing international regulatory frameworks and norms for responsible space operations. She brings extensive experience in space policy from prior roles in government and industry.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512